Skip to main content

Table 1 Safety—serious and non-serious adverse events up to 6 months post intervention

From: Phase I and registry study of autologous bone marrow concentrate evaluated in PDE5 inhibitor refractory erectile dysfunction

Caverstem intervention

1.0 low dose

1.0 high dose

2.0

Number of patients

20

20

100

Serious adverse event

0 (0)

0 (0)

0 (0)

Loss of injection product (n)

0 (0)

0 (0)

0 (0)

Total volume injected (mL)

3

6

20

Injection of allocated amount of product (n)

20 (100)

20 (100)

100 (100)

Adverse event                                                                                                                                          

n(%)

n(%)

n(%)

 Pain at harvest sitea

5 (25)

7 (35)

9 (9)

 Pain at injection sitea

6 (30)

6 (30)

5 (5)

 Brushing at harvest sitea

5 (25)

5 (25)

6 (6)

 Bruising at injection sitea

3 (15)

4 (20)

4 (4)

 Negative impact on penisb

0 (0)

0 (0)

0 (0)

 Fevers

0 (0)

0 (0)

0 (0)

 Infection

0 (0)

0 (0)

0 (0)

  1. aGreater than 24 h post procedure
  2. bAs perceived by the patient